Provided is a polypeptide, a production method therefor and a use thereof. The polypeptide includes 63 to 1496 continuous amino acid residues of SEQ ID NO: 9, and includes a sequence represented by (A).sub.m or is composed of the sequence represented by (A).sub.m, wherein each A is an amino acid sequence selected from any one of those represented by SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, or a modified amino acid sequence or a sequence variant thereof; m is an integer between 1 and 10; and each A is the same or different and two adjacent As are directly connected by peptide bonds or connected by at least one amino acid residue, wherein the polypeptide has a cell adhesion activity, and a method of producing said polypeptide and use of said polypeptide.

Described herein are protein nanoparticles comprising a fusion protein comprising at least one binding polypeptide and at least one unstructured polypeptide, in one aspect, the nanoparticles comprise a di-block of repeats of a core polypeptide, repeats of a corona polypeptide, and one or more binding proteins. The nanoparticles can be used as therapeutic agents, targeted-delivery agents, separation agents, or purification agents.

Described herein are protein nanoparticles comprising a fusion protein comprising at least one binding polypeptide and at least one unstructured polypeptide, in one aspect, the nanoparticles comprise a di-block of repeats of a core polypeptide, repeats of a corona polypeptide, and one or more binding proteins. The nanoparticles can be used as therapeutic agents, targeted-delivery agents, separation agents, or purification agents.

The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions containing said polypeptides and methods of using the polypeptides to treat diseases and conditions including neuromuscular diseases, osteogenesis imperfecta, myelofibrosis, thrombocytopenia, neutropenia, and metabolic disease.

The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions containing said polypeptides and methods of using the polypeptides to treat diseases and conditions including neuromuscular diseases, osteogenesis imperfecta, myelofibrosis, thrombocytopenia, neutropenia, and metabolic disease.

The present invention relates to recombinant laminin adeno-associated viral vector (AAV) constructs and related methods for restoring laminin expression in deficient mammals, or in mammals with basement membrane instability.

The present invention relates to recombinant laminin adeno-associated viral vector (AAV) constructs and related methods for restoring laminin expression in deficient mammals, or in mammals with basement membrane instability.

A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.

A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.

Antimicrobial peptides of general formula X.sub.0X.sub.1X.sub.2CX.sub.3X.sub.4X.sub.5CX.sub.6X.sub.7X.sub.8X.sub.9CYX.sub.10X.sub.11CX.sub.12X.sub.13 are provided. Also provided are certain formulations containing these peptides and methods of using these peptides for treating skin infections in an animal in need thereof.